Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting

British Journal of Clinical Pharmacology

Volumn 70, Issue 5, 2010, Pages 656-663

  Duran, Marta ^a   Pérez, Eulàlia ^a   Abanades, Sergio ^b   Vidal, Xavier ^a   Saura, Cristina ^a   Majem, Margarita ^c   Arriola, Edurne ^b   Rabanal, Manel ^d   Pastor, Antoni ^b   Farré, Magí ^b   Rams, Neus ^d   Laporte, Joan Ramon ^a   Capellà, Dolors ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Adverse effects; Anti emetic agents; Antineoplastic agents; Cannabis; Clinical trial; Nausea; Vomiting

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CANNABIDIOL; CANNABIS; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DRONABINOL; EPIRUBICIN; GRANISETRON; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; METOCLOPRAMIDE; MITOXANTRONE; NABILONE; ONDANSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ADD ON THERAPY; ADULT; AEROPHAGIA; AGED; ANOREXIA; ANXIETY DISORDER; ARTICLE; BLURRED VISION; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE CONTROL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EPIGASTRIC PAIN; EUPHORIA; FATIGUE; FEELING ABNORMAL; FEMALE; HUMAN; INSOMNIA; MALE; MEMORY DISORDER; MOUTH PAIN; MOUTH ULCER; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; THROAT IRRITATION; TREATMENT RESPONSE; VISUAL HALLUCINATION; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CANNABIDIOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; PILOT PROJECTS; TETRAHYDROCANNABINOL; VOMITING;

EID: 78649287164     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03743.x     Document Type: Article

References (20)

1. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006; 24: 4472-8.
2. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2006. J Clin Oncol 2006; 24: 2932-47.
3. Slatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol 2007; 5 (Suppl. 3) S1-9.
4. Duran M, de las Heras MJ, Laporte JR, Capellà D. Uso terapéutico del cannabis: resultados de una entrevista prospectiva en Cataluña. Med Clin (Barc) 2005; 124: 76-7.
5. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199-215.
6. Sanger GJ. Endocannabinoids and the gastrointestinal tract: what are the key questions? Br J Pharmacol 2007; 152: 663-70.
7. Van Sickle DD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310: 329-32.
8. Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting, quantitative systematic review. BMJ 2001; 323: 16-21.
9. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42: 327-60.
10. Parker LA, Mechoulam R, Schlievert C. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 2002; 13: 567-70.
11. Di Marzo V, Petrocelli LD. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 2006; 57: 553-74.
12. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-9.
13. Colin C, Davies P, Mutiboko IK, Ratcliffe S, Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14: 290-6.
14. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12: 639-45.
15. Carnrike CLM, Brantley PJ, Bruce B, Faruqui S, Gresham FM, Buss RR, Cocke TB. Test-retest reliability and concurrent validity of the Morrow assessment of nausea and emesis (MANE) for the assessment of cancer chemotherapy-related nausea and vomiting. J Psychopathol Behav Assess 1988; 10:105-16.
16. Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 2003; 11: 522-7.
17. Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, Abusada GA. Cannabinoids in humans. I. Analysis of delta 9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS. J Anal Toxicol 1995; 19: 285-91.
18. Newcombe RG, Altman DG. Proportions and their differences. In: Statistics with Confidence, eds Altman DG, Machin D, Bryant TN, Gardner MJ. London: BMJ Publishing Books, 2000; 49-50.
19. Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, Baranowski V. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 2007; 23: 533-43.
20. Smith PF. GW-1000.GW Pharmaceuticals. Curr Opin Investig Drugs 2004; 5: 748-54.